Yang J M, Southern J F, Warshaw A L, Lewandrowski K B
Department of Pathology, Massachusetts General Hospital, Boston 02114, USA.
Am J Surg. 1996 Jan;171(1):126-9; discussion 129-30. doi: 10.1016/S0002-9610(99)80086-5.
Cystic lesions of the pancreas include inflammatory pseudocysts, serous cystadenomas, and mucinous cystic tumors, some of which are malignant. Previous studies have shown that malignant mucinous tumors differ from benign pancreatic cysts in proliferative activity, secretion of tumor markers, and expression of growth factor receptors. Analysis of aspirated cyst fluid for tumor markers, viscosity, and cytologic examination has been proposed as an aid to preoperative differential diagnosis. Tissue polypeptide antigen (TPA) is a soluble proliferation antigen produced by rapidly dividing tissues, including conventional ductal pancreatic carcinoma. TPA levels in pancreatic cyst fluids have not been reported.
Tissue polypeptide antigen levels were determined in 46 pancreatic cyst fluids using a commercial immunoassay technique.
Mucinous cystadenocarcinomas exhibited significantly higher levels of cyst fluid TPA than benign cystic lesions, including pseudocysts, serous cystadenomas, and benign mucinous cystadenomas (mean 910,672 U/mL, median 300,900 U/mL, range 16,600 to 4,210,000 U/mL for malignant mucinous cystadenocarcinomas; versus mean 16,082 U/mL, median 2,455 U/mL, range 0 to 155,000 U/mL for benign cystic lesions considered as a group; P < 0.0002). In 75% of the malignant cysts, the TPA values were in excess of 100,000 U/mL. Pseudocysts exhibited the lowest TPA levels (mean 2,108 U/mL, median 604 U/mL, range 0 to 20,240 U/mL) and were significantly lower than the values observed in cystic tumors (P < 0.0005). Serous and benign mucinous tumors had intermediate levels of TPA.
Elevated levels of the proliferation antigen TPA in malignant pancreatic cysts correlate with earlier observations of increased proliferative activity and overexpression of growth factor receptors in these tumors. The TPA measurement may be a useful addition to previously reported cyst fluid markers to aid in preoperative differential diagnosis. Markedly elevated or very low values indicate a malignant or benign cyst, respectively.
胰腺囊性病变包括炎性假囊肿、浆液性囊腺瘤和黏液性囊性肿瘤,其中一些是恶性的。先前的研究表明,恶性黏液性肿瘤在增殖活性、肿瘤标志物分泌和生长因子受体表达方面与良性胰腺囊肿不同。对抽吸的囊液进行肿瘤标志物、黏度分析及细胞学检查已被提议作为术前鉴别诊断的辅助手段。组织多肽抗原(TPA)是一种由快速分裂组织产生的可溶性增殖抗原,包括传统的胰腺导管癌。胰腺囊液中的TPA水平尚未见报道。
采用商业免疫测定技术测定46份胰腺囊液中的组织多肽抗原水平。
黏液性囊腺癌囊液TPA水平显著高于良性囊性病变,包括假囊肿、浆液性囊腺瘤和良性黏液性囊腺瘤(恶性黏液性囊腺癌平均910,672 U/mL,中位数300,9oo U/mL,范围16,600至4,210,000 U/mL;而作为一组的良性囊性病变平均16,082 U/mL,中位数2,455 U/mL,范围0至155,000 U/mL;P<0.0002)。75%的恶性囊肿TPA值超过100,000 U/mL。假囊肿TPA水平最低(平均2,108 U/mL,中位数604 U/mL,范围0至20,240 U/mL),显著低于囊性肿瘤中的观察值(P<0.0005)。浆液性和良性黏液性肿瘤TPA水平处于中间值。
恶性胰腺囊肿中增殖抗原TPA水平升高与这些肿瘤中增殖活性增加和生长因子受体过表达的早期观察结果相关。TPA测量可能是先前报道的囊液标志物的有益补充,有助于术前鉴别诊断。明显升高或极低的值分别表明为恶性或良性囊肿。